OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Recent advances in therapies for primary myelofibrosis
William Vainchenker, Nasrine Yahmi, Violaine Havelange, et al.
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
William Vainchenker, Nasrine Yahmi, Violaine Havelange, et al.
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
Showing 7 citing articles:
Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 5, pp. e383-e389
Closed Access | Times Cited: 5
Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 5, pp. e383-e389
Closed Access | Times Cited: 5
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Nature Medicine (2025)
Open Access
Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Nature Medicine (2025)
Open Access
Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms
Safa Daoud, Mutasem O. Taha
Expert Opinion on Drug Discovery (2024), pp. 1-13
Closed Access | Times Cited: 3
Safa Daoud, Mutasem O. Taha
Expert Opinion on Drug Discovery (2024), pp. 1-13
Closed Access | Times Cited: 3
Age‐associated myeloid malignancies – the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia
Eirini S. Fasouli, Eleni Katsantoni
FEBS Letters (2024) Vol. 598, Iss. 22, pp. 2809-2828
Open Access | Times Cited: 2
Eirini S. Fasouli, Eleni Katsantoni
FEBS Letters (2024) Vol. 598, Iss. 22, pp. 2809-2828
Open Access | Times Cited: 2
Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG
Ziqi Guo, Yaping Liu, Xin Li, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Ziqi Guo, Yaping Liu, Xin Li, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Identifying disease-modifying potential in myelofibrosis clinical trials
David M. Ross, Steven Lane, Claire Harrison
Blood (2024) Vol. 144, Iss. 16, pp. 1679-1688
Closed Access | Times Cited: 1
David M. Ross, Steven Lane, Claire Harrison
Blood (2024) Vol. 144, Iss. 16, pp. 1679-1688
Closed Access | Times Cited: 1
Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a murine model
Ernesto José Cuenca‐Zamora, Constantino Martı́nez, María Luz Morales, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117712-117712
Open Access
Ernesto José Cuenca‐Zamora, Constantino Martı́nez, María Luz Morales, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117712-117712
Open Access
